Unliganded progesterone receptors attenuate taxane-induced breast cancer cell death by modulating the spindle assembly checkpoint

Breast Cancer Research and Treatment

Volumn 131, Issue 1, 2012, Pages 75-87

  Badtke, Melanie M ^a   Jambal, Purevsuren ^a   Dye, Wendy W ^a   Spillman, Monique A ^a   Post, Miriam D ^a   Horwitz, Kathryn B ^a   Jacobsen, Britta M ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

Breast cancer; Cell death; Multinucleation; Progesterone receptor; Spindle assembly checkpoint; Taxane

Indexed keywords

ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; PROGESTERONE RECEPTOR A; PROGESTERONE RECEPTOR B; TAXANE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CANCER RESISTANCE; CELL DEATH; CELL PROTECTION; CELL SURVIVAL; CENTROMERE; CONTROLLED STUDY; FEMALE; GENE CONTROL; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; IN VITRO STUDY; M PHASE CELL CYCLE CHECKPOINT; MICROTUBULE ASSEMBLY; MITOSIS; MOUSE; MULTINUCLEAR CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR XENOGRAFT;

ANIMALS; APOPTOSIS; BREAST NEOPLASMS; BRIDGED COMPOUNDS; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HELA CELLS; HUMANS; M PHASE CELL CYCLE CHECKPOINTS; MICE; MICE, NUDE; MICROTUBULES; MITOSIS; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SIGNAL TRANSDUCTION; TAXOIDS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84856218107     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-011-1399-0     Document Type: Article

References (56)

1. PM Ravdin HA Burris III G Cook P Eisenberg M Kane WA Bierman J Mortimer E Genevois RE Bellet 1995 Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer J Clin Oncol 13 12 2879 2885 8523050 1:CAS:528:DyaK28XmslOntw%3D%3D
2. V Valero SE Jones DD Von Hoff DJ Booser RG Mennel PM Ravdin FA Holmes Z Rahman MW Schottstaedt JK Erban L Esparza-Guerra RH Earhart GN Hortobagyi HA Burris 3rd 1998 A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer J Clin Oncol 16 10 3362 3368 9779713 1:CAS:528:DyaK1cXmvFGrtbc%3D (Pubitemid 28481633)
3. M Sawaki Y Ito D Hashimoto N Mizunuma S Takahashi N Horikoshi K Tada F Kasumi F Akiyama G Sakamoto T Imai A Nakao K Hatake 2004 Paclitaxel administered weekly in patients with docetaxel-resistant metastatic breast cancer: a single-center study Tumori 90 1 36 39 15143969 1:CAS:528:DC%2BD2cXkvVakurw%3D (Pubitemid 38541724)
4. BT McGrogan B Gilmartin DN Carney A McCann 2008 Taxanes, microtubules and chemoresistant breast cancer Biochim Biophys Acta 1785 2 96 132 1016/j.bbcan.2007.10.004 18068131 1:CAS:528:DC%2BD1cXkvFWlu78%3D
5. DJ Villeneuve SL Hembruff Z Veitch M Cecchetto WA Dew AM Parissenti 2006 cDNA microarray analysis of isogenic paclitaxel- and doxorubicin-resistant breast tumor cell lines reveals distinct drug-specific genetic signatures of resistance Breast Cancer Res Treat 96 1 17 39 16322897 10.1007/s10549-005-9026-6 1:CAS:528:DC%2BD28XivVensbc%3D
6. JG Chen CP Yang M Cammer SB Horwitz 2003 Gene expression and mitotic exit induced by microtubule-stabilizing drugs Cancer Res 63 22 7891 7899 14633718 1:CAS:528:DC%2BD3sXptFOlt7k%3D (Pubitemid 37466724)
7. H Hernandez-Vargas J Palacios G Moreno-Bueno 2007 Molecular profiling of docetaxel cytotoxicity in breast cancer cells: uncoupling of aberrant mitosis and apoptosis Oncogene 26 20 2902 2913 10.1038/sj.onc.1210102 17099726 10.1038/sj.onc.1210102 1:CAS:528:DC%2BD2sXkvVansbk%3D (Pubitemid 46701448)
8. CJ Creighton X Li M Landis JM Dixon VM Neumeister A Sjolund DL Rimm H Wong A Rodriguez JI Herschkowitz C Fan X Zhang X He A Pavlick MC Gutierrez L Renshaw AA Larionov D Faratian SG Hilsenbeck CM Perou MT Lewis JM Rosen JC Chang 2009 Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features Proc Natl Acad Sci USA 106 33 13820 13825 10.1073/pnas.0905718106 19666588 10.1073/pnas.0905718106 1:CAS:528: DC%2BD1MXhtFWksLjF
9. JC Harrell WW Dye DC Allred P Jedlicka NS Spoelstra CA Sartorius KB Horwitz 2006 Estrogen receptor positive breast cancer metastasis: altered hormonal sensitivity and tumor aggressiveness in lymphatic vessels and lymph nodes Cancer Res 66 18 9308 9315 16982776 10.1158/0008-5472.CAN-06-1769 1:CAS:528:DC%2BD28Xps1ahsrY%3D (Pubitemid 44521153)
10. Ghersi D, Wilcken N, Simes J, Donoghue E (2005) Taxane containing regimens for metastatic breast cancer. Cochrane Database Syst Rev (2):CD003366. doi: 10.1002/14651858.CD003366.pub2
11. IC Henderson DA Berry GD Demetri CT Cirrincione LJ Goldstein S Martino JN Ingle MR Cooper DF Hayes KH Tkaczuk G Fleming JF Holland DB Duggan JT Carpenter E Frei 3rd RL Schilsky WC Wood HB Muss L Norton 2003 Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer J Clin Oncol 21 6 976 983 12637460 10.1200/JCO.2003.02.063 1:CAS:528:DC%2BD2cXpsVGqs7c%3D (Pubitemid 46594124)
12. M Sui Y Huang BH Park NE Davidson W Fan 2007 Estrogen receptor alpha mediates breast cancer cell resistance to paclitaxel through inhibition of apoptotic cell death Cancer Res 67 11 5337 5344 17545614 10.1158/0008-5472.CAN- 06-4582 1:CAS:528:DC%2BD2sXmtVait78%3D (Pubitemid 46997273)
13. MK Dougherty LM Schumaker VC Jordan WV Welshons EM Curran MJ Ellis D El-Ashry 2004 Estrogen receptor expression and sensitivity to paclitaxel in breast cancer Cancer Biol Ther 3 5 460 467 15020841 1:CAS:528: DC%2BD2MXhtFGmtrs%3D (Pubitemid 41350861)
14. M Schmidt E Bremer D Hasenclever A Victor M Gehrmann E Steiner IB Schiffer S Gebhardt HA Lehr M Mahlke M Hermes A Mustea B Tanner H Koelbl H Pilch JG Hengstler 2007 Role of the progesterone receptor for paclitaxel resistance in primary breast cancer Br J Cancer 96 2 241 247 17211474 10.1038/sj.bjc. 6603538 1:CAS:528:DC%2BD2sXotFeltg%3D%3D (Pubitemid 46160628)
15. K Miller M Wang J Gralow M Dickler M Cobleigh EA Perez T Shenkier D Cella NE Davidson 2007 Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer N Engl J Med 357 26 2666 2676 18160686 10.1056/NEJMoa072113 1:CAS:528:DC%2BD1cXisVOnsg%3D%3D
16. BM Jacobsen SA Schittone JK Richer KB Horwitz 2005 Progesterone- independent effects of human progesterone receptors (PRs) in estrogen receptor-positive breast cancer: PR isoform-specific gene regulation and tumor biology Mol Endocrinol 19 3 574 587 15563544 10.1210/me.2004-0287 1:CAS:528:DC%2BD2MXit1Srur0%3D (Pubitemid 40349432)
17. BM Jacobsen JK Richer SA Schittone KB Horwitz 2002 New human breast cancer cells to study progesterone receptor isoform ratio effects and ligand-independent gene regulation J Biol Chem 277 31 27793 27800 12021276 10.1074/jbc.M202584200 1:CAS:528:DC%2BD38XlvFKgtr8%3D (Pubitemid 34966724)
18. RP Ghatge BM Jacobsen SA Schittone KB Horwitz 2005 The progestational and androgenic properties of medroxyprogesterone acetate: gene regulatory overlap with dihydrotestosterone in breast cancer cells Breast Cancer Res 7 6 R1036 R1050 10.1186/bcr1340 16457685 10.1186/bcr1340 1:CAS:528:DC%2BD2MXht1ylt73L
19. EL Bradshaw-Pierce SG Eckhardt DL Gustafson 2007 A physiologically based pharmacokinetic model of docetaxel disposition: from mouse to man Clin Cancer Res 13 9 2768 2776 10.1158/1078-0432.CCR-06-2362 17473210 10.1158/1078-0432.CCR- 06-2362 1:CAS:528:DC%2BD2sXkslOhu78%3D (Pubitemid 46788046)
20. DJ McCarthy GK Smyth 2009 Testing significance relative to a fold-change threshold is a TREAT Bioinformatics 25 6 765 771 10.1093/bioinformatics/btp053 19176553 10.1093/bioinformatics/btp053 1:CAS:528:DC%2BD1MXjt1ektL8%3D
21. HY Yamada GJ Gorbsky 2006 Spindle checkpoint function and cellular sensitivity to antimitotic drugs Mol Cancer Ther 5 12 2963 2969 10.1158/1535-7163.MCT-06-0319 17172401 10.1158/1535-7163.MCT-06-0319 1:CAS:528:DC%2BD28Xhtlagsb3O (Pubitemid 46092037)
22. BE Keyes CM Yellman DJ Burke 2008 Differential regulation of anaphase promoting complex/cyclosome substrates by the spindle assembly checkpoint in Saccharomyces cerevisiae Genetics 178 1 589 591 10.1534/genetics.107.083642 18202397 10.1534/genetics.107.083642 1:CAS:528:DC%2BD1cXhs12lt7c%3D (Pubitemid 351398772)
23. L Magnaghi-Jaulin G Eot-Houllier G Fulcrand C Jaulin 2007 Histone deacetylase inhibitors induce premature sister chromatid separation and override the mitotic spindle assembly checkpoint Cancer Res 67 13 6360 6367 10.1158/0008-5472.CAN-06-3012 17616695 10.1158/0008-5472.CAN-06-3012 1:CAS:528:DC%2BD2sXnsVyqtLs%3D (Pubitemid 47037519)
24. JC Chang EC Wooten A Tsimelzon SG Hilsenbeck MC Gutierrez R Elledge S Mohsin CK Osborne GC Chamness DC Allred P O'Connell 2003 Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer Lancet 362 9381 362 369 12907009 10.1016/S0140-6736(03)14023- 8 1:CAS:528:DC%2BD3sXlvFGnsLo%3D (Pubitemid 36957839)
25. K Iwao-Koizumi R Matoba N Ueno SJ Kim A Ando Y Miyoshi E Maeda S Noguchi K Kato 2005 Prediction of docetaxel response in human breast cancer by gene expression profiling J Clin Oncol 23 3 422 431 10.1200/JCO.2005.09.078 15659489 10.1200/JCO.2005.09.078 1:CAS:528:DC%2BD2MXitVarsbw%3D (Pubitemid 46224217)
26. H Zembutsu Y Suzuki A Sasaki T Tsunoda M Okazaki M Yoshimoto T Hasegawa K Hirata Y Nakamura 2009 Predicting response to docetaxel neoadjuvant chemotherapy for advanced breast cancers through genome-wide gene expression profiling Int J Oncol 34 2 361 370 19148470 1:CAS:528:DC%2BD1MXisVGju78%3D
27. L Gianni M Zambetti K Clark J Baker M Cronin J Wu G Mariani J Rodriguez M Carcangiu D Watson P Valagussa R Rouzier WF Symmans JS Ross GN Hortobagyi L Pusztai S Shak 2005 Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer J Clin Oncol 23 29 7265 7277 16145055 10.1200/JCO.2005.02.0818 1:CAS:528:DC%2BD2MXhtF2nsL3K (Pubitemid 46202341)
28. P Schoffski 2009 Polo-like kinase (PLK) inhibitors in preclinical and early clinical development in oncology Oncologist 14 6 559 570 10.1634/theoncologist.2009-0010 19474163 10.1634/theoncologist.2009-0010 1:CAS:528:DC%2BD1MXosl2hu7g%3D
29. BM Ryan N O'Donovan MJ Duffy 2009 Survivin: a new target for anti-cancer therapy Cancer Treat Rev 35 7 553 562 10.1016/j.ctrv.2009.05.003 19559538 10.1016/j.ctrv.2009.05.003 1:CAS:528:DC%2BD1MXhtlCgt7zM
30. KW Wood L Lad L Luo X Qian SD Knight N Nevins K Brejc D Sutton AG Gilmartin PR Chua R Desai SP Schauer DE McNulty RS Annan LD Belmont C Garcia Y Lee MA Diamond LF Faucette M Giardiniere S Zhang CM Sun JD Vidal S Lichtsteiner WD Cornwell JD Greshock RF Wooster JT Finer RA Copeland PS Huang DJ Morgans Jr. D Dhanak G Bergnes R Sakowicz Jr. Jackson 2010 Antitumor activity of an allosteric inhibitor of centromere-associated protein-E Proc Natl Acad Sci USA 107 13 5839 5844 10.1073/pnas.0915068107 20167803 10.1073/pnas.0915068107 1:CAS:528:DC%2BC3cXks1Kksbo%3D
31. CH Cheung MS Coumar HP Hsieh JY Chang 2009 Aurora kinase inhibitors in preclinical and clinical testing Expert Opin Investig Drugs 18 4 379 398 10.1517/13543780902806392 19335272 10.1517/13543780902806392 1:CAS:528:DC%2BD1MXjvVWnsLo%3D
32. K Sasai JM Parant ME Brandt J Carter HP Adams SA Stass AM Killary H Katayama S Sen 2008 Targeted disruption of Aurora A causes abnormal mitotic spindle assembly, chromosome misalignment and embryonic lethality Oncogene 27 29 4122 4127 10.1038/onc.2008.47 18345035 10.1038/onc.2008.47 1:CAS:528: DC%2BD1cXnvFyrs7o%3D (Pubitemid 351931992)
33. M Schliekelman DO Cowley R O'Quinn TG Oliver L Lu ED Salmon T Van Dyke 2009 Impaired Bub1 function in vivo compromises tension-dependent checkpoint function leading to aneuploidy and tumorigenesis Cancer Res 69 1 45 54 10.1158/0008-5472.CAN-07-6330 19117986 10.1158/0008-5472.CAN-07-6330 1:CAS:528:DC%2BD1MXmvFOi
34. FR Putkey T Cramer MK Morphew AD Silk RS Johnson Jr. McIntosh DW Cleveland 2002 Unstable kinetochore-microtubule capture and chromosomal instability following deletion of CENP-E Dev Cell 3 3 351 365 12361599 10.1016/S1534-5807(02)00255-1 1:CAS:528:DC%2BD38XntlCqtrs%3D
35. LS Michel V Liberal A Chatterjee R Kirchwegger B Pasche W Gerald M Dobles PK Sorger VV Murty R Benezra 2001 MAD2 haplo-insufficiency causes premature anaphase and chromosome instability in mammalian cells Nature 409 6818 355 359 10.1038/35053094 11201745 10.1038/35053094 1:STN:280:DC%2BD3M7hvVOnug%3D%3D (Pubitemid 32151241)
36. A Musio C Montagna D Zambroni E Indino O Barbieri L Citti A Villa T Ried P Vezzoni 2003 Inhibition of BUB1 results in genomic instability and anchorage-independent growth of normal human fibroblasts Cancer Res 63 11 2855 2863 12782591 1:CAS:528:DC%2BD3sXkt1aisLk%3D (Pubitemid 36667157)
37. DP Cahill C Lengauer J Yu GJ Riggins JK Willson SD Markowitz KW Kinzler B Vogelstein 1998 Mutations of mitotic checkpoint genes in human cancers Nature 392 6673 300 303 10.1038/32688 9521327 10.1038/32688 1:CAS:528: DyaK1cXitFahsro%3D (Pubitemid 28155105)
38. L Michel E Diaz-Rodriguez G Narayan E Hernando VV Murty R Benezra 2004 Complete loss of the tumor suppressor MAD2 causes premature cyclin B degradation and mitotic failure in human somatic cells Proc Natl Acad Sci USA 101 13 4459 4464 10.1073/pnas.0306069101 15070740 10.1073/pnas.0306069101 1:CAS:528:DC%2BD2cXjtFKju7g%3D (Pubitemid 38437433)
39. B Yuan Y Xu JH Woo Y Wang YK Bae DS Yoon RP Wersto E Tully K Wilsbach E Gabrielson 2006 Increased expression of mitotic checkpoint genes in breast cancer cells with chromosomal instability Clin Cancer Res 12 2 405 410 10.1158/1078-0432.CCR-05-0903 16428479 10.1158/1078-0432.CCR-05-0903 1:CAS:528:DC%2BD28XmtlKjtw%3D%3D (Pubitemid 43166128)
40. R Sotillo E Hernando E Diaz-Rodriguez J Teruya-Feldstein C Cordon-Cardo SW Lowe R Benezra 2007 Mad2 overexpression promotes aneuploidy and tumorigenesis in mice Cancer Cell 11 1 9 23 10.1016/j.ccr.2006.10.019 17189715 10.1016/j.ccr.2006.10.019 1:CAS:528:DC%2BD2sXhtFKmt74%3D (Pubitemid 46054519)
41. S Anand S Penrhyn-Lowe AR Venkitaraman 2003 AURORA-A amplification overrides the mitotic spindle assembly checkpoint, inducing resistance to Taxol Cancer Cell 3 1 51 62 12559175 10.1016/S1535-6108(02)00235-0 1:CAS:528:DC%2BD3sXhtFamt7Y%3D (Pubitemid 37443890)
42. DR Wysong A Chakravarty K Hoar JA Ecsedy 2009 The inhibition of Aurora A abrogates the mitotic delay induced by microtubule perturbing agents Cell Cycle 8 6 876 888 19221504 10.4161/cc.8.6.7897 1:CAS:528:DC%2BD1MXlvFWisL8%3D
43. JL Merlin C Bour-Dill S Marchal L Bastien MP Gramain 2000 Resistance to paclitaxel induces time-delayed multinucleation and DNA fragmentation into large fragments in MCF-7 human breast adenocarcinoma cells Anticancer Drugs 11 4 295 302 10898546 10.1097/00001813-200004000-00011 1:CAS:528:DC%2BD3cXkvVynsrk%3D (Pubitemid 30416960)
44. R Panvichian K Orth ML Day KC Day MJ Pilat KJ Pienta 1998 Paclitaxel-associated multimininucleation is permitted by the inhibition of caspase activation: a potential early step in drug resistance Cancer Res 58 20 4667 4672 9788620 1:CAS:528:DyaK1cXmslWrsb8%3D (Pubitemid 28480633)
45. AN Makarovskiy E Siryaporn DC Hixson W Akerley 2002 Survival of docetaxel-resistant prostate cancer cells in vitro depends on phenotype alterations and continuity of drug exposure Cell Mol Life Sci 59 7 1198 1211 12222966 10.1007/s00018-002-8498-3 1:CAS:528:DC%2BD38Xmtlers70%3D
46. Jr. Roberts DC Allison RC Donehower EK Rowinsky 1990 Development of polyploidization in taxol-resistant human leukemia cells in vitro Cancer Res 50 3 710 716 1967550 1:CAS:528:DyaK3cXhtlajsLc%3D (Pubitemid 20054203)
47. AL Blajeski TJ Kottke SH Kaufmann 2001 A multistep model for paclitaxel-induced apoptosis in human breast cancer cell lines Exp Cell Res 270 2 277 288 10.1006/excr.2001.5349 11640891 10.1006/excr.2001.5349 1:CAS:528:DC%2BD3MXns1aju70%3D (Pubitemid 33030166)
48. J Erenpreisa A Ivanov SP Wheatley EA Kosmacek F Ianzini AP Anisimov M Mackey PJ Davis G Plakhins TM Illidge 2008 Endopolyploidy in irradiated p53-deficient tumour cell lines: persistence of cell division activity in giant cells expressing Aurora-B kinase Cell Biol Int 32 9 1044 1056 10.1016/j.cellbi.2008.06.003 18602486 10.1016/j.cellbi.2008.06.003 1:CAS:528:DC%2BD1cXhtVens7jE
49. A Ivanov MS Cragg J Erenpreisa D Emzinsh H Lukman TM Illidge 2003 Endopolyploid cells produced after severe genotoxic damage have the potential to repair DNA double strand breaks J Cell Sci 116 Pt 20 4095 4106 10.1242/jcs.00740 12953071 10.1242/jcs.00740 1:CAS:528:DC%2BD3sXovFWmsLY%3D (Pubitemid 37337084)
50. ME Bekier R Fischbach J Lee WR Taylor 2009 Length of mitotic arrest induced by microtubule-stabilizing drugs determines cell death after mitotic exit Mol Cancer Ther 8 6 1646 1654 10.1158/1535-7163.MCT-08-1084 19509263 10.1158/1535-7163.MCT-08-1084 1:CAS:528:DC%2BD1MXntVKgtrY%3D
51. S Classen K Possinger R Pelka-Fleischer W Wilmanns 1993 Effect of onapristone and medroxyprogesterone acetate on the proliferation and hormone receptor concentration of human breast cancer cells J Steroid Biochem Mol Biol 45 4 315 319 8499339 10.1016/0960-0760(93)90348-Z 1:CAS:528:DyaK3sXks1entb0%3D (Pubitemid 23166565)
52. R Hackenberg K Hannig S Beck P Schmidt-Rhode A Scholz KD Schulz 1996 Androgen-like and anti-androgen-like effects of antiprogestins in human mammary cancer cells Eur J Cancer 32A 4 696 701 8695275 10.1016/0959-8049(95)00616-8 1:CAS:528:DyaK28XjsFSqs7s%3D
53. G Romieu T Maudelonde A Ulmann H Pujol J Grenier G Cavalie S Khalaf H Rochefort 1987 The antiprogestin RU486 in advanced breast cancer: preliminary clinical trial Bull Cancer 74 4 455 461 3311238 1:STN:280:DyaL1c%2FisFKktA%3D%3D (Pubitemid 17135278)
54. RZC Maibauer M Schultz-Mosgau B Rohde I Kuss W Sittner AG Scherling 2006 Abstract #4074: First human data for ZK 230211 (ZK-PRA), a new progesterone receptor antagonist: a phase I clinical analysis of safety and pharmakokinetics in healthy postmenopausal women Breast Cancer Res Treat 100 Supplement 1 S196
55. J Erenpreisa MS Cragg 2001 Mitotic death: a mechanism of survival? A review Cancer Cell Int 1 1 1 11983025 10.1186/1475-2867-1-1 (Pubitemid 38751048)
56. TM Illidge MS Cragg B Fringes P Olive JA Erenpreisa 2000 Polyploid giant cells provide a survival mechanism for p53 mutant cells after DNA damage Cell Biol Int 24 9 621 633 10.1006/cbir.2000.0557 10964452 10.1006/cbir.2000.0557 1:CAS:528:DC%2BD3cXmtVGgtbY%3D